Wall Street analysts change outlook on top names. Check analyst ratings page for all changes. See what analysts say about LYEL, IMRX, and RNA.
Stifel and HC Wainwright initiate Buy coverage on immunopharma trio (LYEL, IMRX, RNA) with targets implying 113-219% upside from current pricing. Market signal: renewed institutional appetite for high-risk biotech pipelines amid consolidation positioning.
Top Wall Street analysts changed their outlook on these top names.
For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Stifel analyst Stephen Willey initiated coverage on Lyell Immunopharma Inc (NASDAQ:LYEL) with a Buy rating and announced a price target of $36.
Lyell Immunopharma closed at $13.45 on Wednesday.
See how other analysts view this stock.
Wall Street analysts changed outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See…
Wall Street analysts changed outlook on top names. For complete changes, see analyst ratings page. AFRM upgraded, LYB raised…
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades,…
Analysts changed outlook on top names, including RXO, AMBQ, BE, ARWR, FSLR. See ratings page for upgrades, downgrades, and…
Wall Street analysts initiated coverage on various top stocks, including VCYT, UMAC, FISN, LTRX, and TNGX with positive ratings…
Top analysts change outlook on top names. See all changes and ratings on our analyst ratings page. Check out what analysts think…
